Filing Details
- Accession Number:
- 0001140361-15-019454
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-05-13 19:00:33
- Reporting Period:
- 2015-05-11
- Filing Date:
- 2015-05-13
- Accepted Time:
- 2015-05-13 19:00:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1416792 | Relypsa Inc | RLYP | Pharmaceutical Preparations (2834) | 260893742 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1283972 | Dr R Klaus Veitinger | C/O Relypsa, Inc. 100 Cardinal Way Redwood City CA 94063 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-05-11 | 5,834 | $3.96 | 8,546 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-05-11 | 5,834 | $36.06 | 2,712 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-05-11 | 5,834 | $0.00 | 5,834 | $3.96 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
69,543 | 2021-09-13 | No | 4 | M | Direct |
Footnotes
- Includes 2,712 restricted stock units.
- The sales reported in this Form 4 were effected pursuant to the Reporting Person's personal Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.0432 to $36.0708, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.